University of Nebraska Medical Center

University of Nebraska Medical Center Research: DigitalCommons@UNMC
Not a member yet
    10909 research outputs found

    Suddenly Stuck: A Classic Case of Thyrotoxicosis Periodic Paralysis

    Get PDF
    N

    Impact of Speed of Seizure Spread on IQ and Post-operative Seizure Freedom in Refractory Epilepsy

    Get PDF
    N

    Needs Assessment of Internal Medicine Learners in Hospital Medicine Competencies

    Get PDF
    N

    Widespread Primary Nodular Cutaneous Amyloidosis Due to Local Plasmacytomas

    Get PDF
    N

    Application of the Karnofsky Performance Scale (KPS) in Inpatient Cancer Rehabilitation

    Get PDF
    N

    Synthesis and Characterization of Zoledronic Acid Prodrugs: A Potential Therapeutic for Enhanced Drug Delivery and Targeted Treatment

    Get PDF
    Bisphosphonates, particularly zoledronic acid (ZA), are crucial in managing bone resorption and treating skeletal disorders like multiple myeloma (MM). While ZA has demonstrated significant anti-myeloma activity in-vitro, its clinical use is limited by poor systemic exposure and potential off-target effects. This thesis investigates two strategies to conjugate polyethylene glycol (PEG) and hyaluronic acid (HA) to ZA to overcome these limitations. The first strategy, targeting the tertiary alcohol group of ZA, faced significant challenges due to the difficulty in conjugation. The second strategy, focusing on the hydroxyl group of the phosphonate moiety in ZA, successfully yielded a ZA-PEG conjugate, enhancing ZA\u27s potency against multiple myeloma cells. Further conjugation with HA aims to improve the targeting capability and therapeutic effectiveness of ZA, enhancing its overall potency in treating multiple myeloma by improving systemic circulation and targetability

    Characterization of Population Pharmacokinetics and Associated Interindividual Variability of Drugs Used in Mass Drug Administration against Lymphatic Filariasis

    Get PDF
    Lymphatic filariasis (LF) is a mosquito-borne filarial infection that affects the lymphatic system. The progression of the disease is associated with severe comorbidities and social stigma among patients. The World Health Organization has categorized the disease as a public health problem, and it has been targeted by mass drug administration (MDA) campaigns over the past two decades. Several preventive chemotherapies have been used in MDA campaigns against LF, including a combination of three anti-filarial drugs (IDA therapy): albendazole (ALB), diethylcarbamazine (DEC), and ivermectin (IVM). Other antiparasitic drugs, such as moxidectin (MOX), are still under investigation for their activity against LF. High inter-individual variability (IIV) in pharmacokinetics has been reported with anti-filarial drugs used in MDA. Addressing IIV, especially for drugs that exhibit significant variability, is critical for optimal dosing to ensure maximum drug efficacy and limiting toxicities. This dissertation aims to characterize the population pharmacokinetics (PopPK) of anti-filarial drugs used in MDA against LF, investigate the reported high IIV, and evaluate different dosing regimens to simplify the existing weight-based dosing. Utilizing drug exposure data from populations living in areas where LF is prevalent, PopPK models for IDA therapy and MOX were developed using non-linear mixed-effect modeling. The presented models showed a good ability to describe the PopPK of MDA drugs, which was evident by the goodness of fit criteria. The covariates analysis showed that sex was a significant explaining part of IIV observed with IVM and DEC. Moreover, the clearance of albendazole sulfoxide (ALB-OX), the active metabolite of ALB, was different between men and women. Weight and microfilaria count at baseline significantly explained part of the variability associated with the volume of distribution of DEC and MOX, respectively. Models-based simulation findings demonstrated that those factors have also affected drug exposure parameters, including maximum plasma concentration (Cmax) and area under the curve (AUC) of IDA and MOX. In MDA campaigns, IVM and DEC are dose-based on body weight, and this dosing regimen could be challenging due to logistic concerns. We have performed a model-based simulation to simulate IVM and DEC exposure after various non-weight-based dosing regimens to simplify the dosing in MDA campaigns. For IVM, the model-based simulation showed higher drug exposure with the experimental 18 mg fixed dose regimen compared with weight-based dosing; however, the increase in drug exposure was relatively small and remained below the plasma threshold associated with emergent side effects. Height-based DEC dosing decreased variability in drug exposure observed with weight-based dosing. In conclusion, the presented work uniquely described PopPK and IIV linked with IDA and MOX therapy in MDA-eligible populations. The developed models can be used for future dose-informing studies to optimize drug dosing and help achieve LF eradication goals

    Structured Laparoscopic Training and Its Impact on Enhancing Ambidexterity in Novice Medical Students

    Get PDF
    This is a published abstract from the UNMC Spotlight on Scholarship 2024

    An Inquiry into the Relationship between Practice Exam Integration, Study Habits, and Perceived Exam Confidence Among First-Year Medical Students at United States Medical School

    Get PDF
    This is a published abstract from the UNMC Spotlight on Scholarship 2024

    7,492

    full texts

    10,909

    metadata records
    Updated in last 30 days.
    University of Nebraska Medical Center Research: DigitalCommons@UNMC
    Access Repository Dashboard
    Do you manage Open Research Online? Become a CORE Member to access insider analytics, issue reports and manage access to outputs from your repository in the CORE Repository Dashboard! 👇